Agios Pharmaceuticals (FRA:8AP) Construction In Progress: €0.00 Mil (As of Mar. 2026)


FRA:8AP Agios Pharmaceuticals Inc FRA:8AP
45 GF Score
Price €31.00
GF Value €73.32
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Construction In Progress?

Agios Pharmaceuticals FRA:8AP -3.13% 45 Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:8AP with a GF Score™ of 45/100 and a GF Value™ of €73.32 (Possible Value Trap). The stock has 4 warning signs investors should review.

Agios Pharmaceuticals's quarterly construction in progress increased from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€2.35 Mil) but then declined from Dec. 2025 (€2.35 Mil) to Mar. 2026 (€0.00 Mil).

Agios Pharmaceuticals's annual construction in progress increased from Dec. 2023 (€0.56 Mil) to Dec. 2024 (€0.86 Mil) and increased from Dec. 2024 (€0.86 Mil) to Dec. 2025 (€2.35 Mil).

Agios Pharmaceuticals Construction In Progress Historical Data

* Premium members only.

The historical data trend for Agios Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agios Pharmaceuticals Construction In Progress Chart

Agios Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.52 0.62 0.56 0.86 2.35

Agios Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 2.35 0.00
FRA:8AP
45GF Score
Agios Pharmaceuticals Inc FRA:8AP
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agios Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.00 Mil mean?
Agios Pharmaceuticals (FRA:8AP) has a Construction In Progress of €0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Agios Pharmaceuticals and its competitors.
Is Agios Pharmaceuticals' Construction In Progress too high?
Agios Pharmaceuticals' current Construction In Progress is €0.00 Mil. Overall, Agios Pharmaceuticals has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' Construction In Progress compare to CAPR and SNDX?
Agios Pharmaceuticals' Construction In Progress of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Agios Pharmaceuticals and its competitors. Agios Pharmaceuticals's current Construction In Progress is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (FRA:8AP) is currently considered Possible Value Trap. The stock's GF Value™ is €73.32, compared to a current price of €31.00 — trading 57.7% below its estimated fair value. The current Construction In Progress is €0.00 Mil. Agios Pharmaceuticals' overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €31.00 is trading 57.7% below its estimated GF Value™ of €73.32. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:8AP:

  • Construction In Progress: €0.00 Mil
  • GF Value™: €73.32 vs. price of €31.00 (57.7% below fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK8AP:Germany
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
45GF Score

Get the complete analysis for FRA:8AP

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.00
Price
€73.32
GF Value